Felic (CIP4b), a novel binding partner with the Src kinase Lyn and Cdc42, localizes to the phagocytic cup

被引:28
作者
Dombrosky-Ferlan, P
Grishin, A
Botelho, RJ
Sampson, M
Wang, L
Rudert, WA
Grinstein, S
Corey, SJ
机构
[1] Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Biochem, Toronto, ON, Canada
[3] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA
关键词
D O I
10.1182/blood-2002-03-0851
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Through its Src homology 3 (SH3) and SH2 domains, the Src kinase Lyn interacts with a small number of phosphoproteins, such as Shc, Cbl, and Vav, which regulate cell cycle and the cytoskeleton. Using Lyn's Unique, SH3, and SH2 domains as bait in a yeast 2-hybrid screen, we isolated a novel gene product with features of a scaffolding protein. We named it Felic because it contains a domain homologous to the tyrosine kinase Fes and the cytoskeletal protein ezrin and forms a Lyn interaction with the GTPase Cdc42 (Felic). Felic was expressed in both hematopoietic and nonhematopoietic tissues. Because it represents an alternative splice product related to the Cdc42-interacting protein 4, CIP4, we also refer to Felic as CIP4b. Felic contains an SH3 recognition site RXPXXP and multiple tyrosine residues. In insulin or serum-stimulated HEK293 cells, Felic became tyrosine phosphorylated. Like CIP4, Felic associated With Cdc42 in its activated form only. Unlike CIP4, Felic does not possess a C-terminal SH3 domain. Coprecipitation studies show that Felic bound to Lyn or activated forms of Cdc42. Overexpression of Felic or CIP4 inhibited NIH 3T3 cell invasiveness in a Matrigel assay. Because Lyn and Cdc42 are involved in phagocytosis, we examined the distribution of Felic in RAW macrophages during particle ingestion. Felic was recruited more efficiently than CIP4 to the phagocytic cups. Altogether, these data suggest that CIP4/Felic constitute a novel family of cytoskeletal scaffolding proteins, integrating Src and Cdc42 pathways. The absence of an SH3 domain in Felic provides a structural basis for functional differences.
引用
收藏
页码:2804 / 2809
页数:6
相关论文
共 38 条
[1]   Vav2 is an activator of Cdc42, Rac1, and RhoA [J].
Abe, K ;
Rossman, KL ;
Liu, B ;
Ritola, KD ;
Chiang, D ;
Campbell, SL ;
Burridge, K ;
Der, CJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (14) :10141-10149
[2]   A Cdc42 target protein with homology to the non-kinase domain of FER has a potential role in regulating the actin cytoskeleton [J].
Aspenstrom, P .
CURRENT BIOLOGY, 1997, 7 (07) :479-487
[3]  
Biscardi JS, 1999, ADV CANCER RES, V76, P61
[4]  
CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033
[5]   Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor [J].
Corey, SJ ;
Dombrosky-Ferlan, PM ;
Zuo, S ;
Krohn, E ;
Donnenberg, AD ;
Zorich, P ;
Romero, G ;
Takata, M ;
Kurosaki, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) :3230-3235
[6]   Requirements for both Rac1 and Cdc42 in membrane ruffling and phagocytosis in leukocytes [J].
Cox, D ;
Chang, P ;
Zhang, Q ;
Reddy, PG ;
Bokoch, GM ;
Greenberg, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (09) :1487-1494
[7]   Src-family tyrosine kinases in activation of ERK-1 and p85/p110-phosphatidylinositol 3-kinase by G/CCKB receptors [J].
Daulhac, L ;
Kowalski-Chauvel, A ;
Pradayrol, L ;
Vaysse, N ;
Seva, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (29) :20657-20663
[8]   Positive and negative roles of the tyrosine kinase Lyn in B cell function [J].
DeFranco, AL ;
Chan, VWF ;
Lowell, CA .
SEMINARS IN IMMUNOLOGY, 1998, 10 (04) :299-307
[9]   Yeast two-hybrid in vivo association of the Src kinase Lyn with the protooncogene product Cbl but not with the p85 subunit of PI 3-kinase [J].
DombroskyFerlan, PM ;
Corey, SJ .
ONCOGENE, 1997, 14 (17) :2019-2024
[10]   Fcγ receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn [J].
Fitzer-Attas, CJ ;
Lowry, M ;
Crowley, MT ;
Finn, AJ ;
Meng, FY ;
DeFranco, AL ;
Lowell, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (04) :669-681